The Scantox Board of Directors is composed of people with vast knowledge and experience within the fields of science, leadership, entrepreneurship and private equity.
Daniel has more than 25 years in senior life science executive roles. In 1996 he joined Pharmacia & Upjohn in clinical drug development. He later moved on and founded TFS International, a global midsized clinical Contract Research Organization with $100+ million in revenues and serving 250 biopharma customers worldwide. Daniel is the recipient of numerous entrepreneurial achievement awards. His expertise covers biopharma- and healthcare services, medical devices, digital health and research technology-enabled services. He is currently serving as Executive Chairman in Trialbee, Board Chairman in Inhalation Sciences, Board NED in Proteros Biostructures, Board NED in NuvoAir and Board NED in Scantox. Daniel holds a technical degree in chemical engineering and an OPM from Harvard Business School. Daniel is based in Boston, USA.
20+ years in pharmaceutical industry, Co-founder, Director Scantox ApS, Head of R&D and CSO Egalet, senior positions in Novo Nordisk, Ferring, Prosidion & Curalogic.
Nicholas joined Impilo in 2020 and is a member of Impilo’s investment committee. Nicholas graduated as Cand. Merc. Mat. From Copenhagen Business School in 2004. Prior to his employment at Impilo he was a Senior Director at EQT Partners where worked from 2006-2019, based both in Copenhagen and New York with a focus on private equity and investments in infrastructure. From 2004-2006 Nicholas worked for Deutsche Bank in London focusing on M&A in the Nordic countries.